Cytosorbents Corp (CTSO) Stock Analysis
Verdict: AVOID
Insider buying at $0.40 provides a temporary floor, but a $12M annual burn against $6.2M in cash forces a dilutive financing event.
Investment score: 38/100
Analysis as of
Is Cytosorbents Corp stock worth reviewing? AI model thesis
CTSO is a high-burn medical device play at a liquidity breaking point. Despite a technical gap-up on insider activity, the fundamentals signal a dilutive death spiral.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 15/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Cytosorbents Corp opportunities and risks
What speaks for CTSO
- Substantial Insider Conviction
What speaks against CTSO
- Immediate Liquidity Crunch
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CTSO | n/a | 0.7x | n/a | 71.0% | -31.9% | -37.1% |
| RDGL | n/a | 399.8x | n/a | -275.6% | -4396.3% | -7.4% |
| NMTC | n/a | 2.9x | n/a | 54.5% | -68.3% | -26.4% |
| PETV | n/a | 19.5x | n/a | 66.0% | -893.3% | -32.5% |
| GTHP | n/a | 29.0x | n/a | 67.9% | -512.6% | -6.1% |
| MODD | n/a | 0.0x | n/a | 0.0% | 0.0% | -240.5% |
| Peer median | n/a | 19.5x | n/a | 54.5% | -512.6% | -26.4% |
Frequently asked questions about Cytosorbents Corp (CTSO)
Is CTSO stock a good investment?
The cached TradeMates AI model rates Cytosorbents Corp as AVOID with an investment score of 38/100. CTSO is a high-burn medical device play at a liquidity breaking point. Despite a technical gap-up on insider activity, the fundamentals signal a dilutive death spiral. This is algorithmic model output, not personal investment advice.
Is CTSO stock a buy?
The TradeMates model verdict for CTSO is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.